$143.8 Million

IsoPlexis Corporation

Initial Public Offering

Bookrunner, October 2021

IsoPlexis Corporation (the “Company”) is facilitating deeper access to in vivo biology and driving durable and potentially transformational research on disease in a new era of advanced medicine. The Company’s single cell proteomics platform, which includes instruments, chip consumables and software, provides an end-to-end solution to reveal a more complete view of protein function at an individual cellular level. The Company’s focus has been on developing applications on its platform for cancer immunology and cell and gene therapy, with ability to expand capabilities to include applications for infectious diseases, inflammatory conditions, and neurological diseases.

More Like This

Sep 2021
$230 Million

Initial Public Offering

Bookrunner

View Details
Sep 2021
$188.5 Million

Initial Public Offering

Co-Manager

View Details
Jun 2021
$122.7 Million

Initial Public Offering

Bookrunner

View Details